Immuneering stock reports a lung cancer study catalyst

Published on 10/05/2026 at 15:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Immuneering stock was trading at USD 4.09 on October 5, 2026, while its Q2 adjusted EPS missed consensus by USD 0.01. A November 6 cancer poster adds a clinical checkpoint.

IMRX, US45254E1073, Illustration mit AI erstellt.

Immuneering stock (ISIN US45254E1073) was trading at USD 4.09 on Nasdaq on October 5, 2026, 51.77 percent below its 52-week high of USD 8.48. The company has scheduled a November 6, 2026, poster on atebimetinib and PD-1 checkpoint blockade at the Society for Immunotherapy of Cancer meeting, giving the clinical pipeline the clearest near-term date on the calendar.

Preclinical data point to lung cancer

According to GlobeNewswire on October 2, 2026, Immuneering said its research poster will show atebimetinib enhancing PD-1 checkpoint blockade in preclinical RAS mutant tumor models. The company linked the findings to a planned Phase 2 study combining atebimetinib with PD-1 blockade in lung cancer patients.

The poster is scheduled for November 6, 2026, at 10:00 a.m. MT, with abstract number 377. The data remain preclinical, so the next value test is whether the proposed combination can translate into a clinical study and eventually support patient treatment.

Loss and cash use frame the pipeline

Immuneering reported diluted GAAP EPS of negative USD 0.27 for Q2 2026, compared with a consensus estimate of negative USD 0.26, a USD 0.01 miss, according to MarketBeat. The finance data shows a Q2 2026 net loss of USD 17.27 million and operating cash flow of negative USD 16.50 million, underscoring the funding demands of late-stage drug development.

MarketBeat lists a Buy consensus based on 7 analysts, with an average target of USD 15.71, a high target of USD 20.00 and a low target of USD 12.00. Against the October 5 trading price, the average target lies 284.1 percent above the price, a wide spread that reflects both development potential and clinical risk.

ESMO adds a second clinical checkpoint

According to Immuneering in its September 24, 2026 release, the company will present a trial-in-progress poster on October 25, 2026, for the Phase 3 MAPKeeper 301 study in first-line metastatic pancreatic cancer. The study evaluates atebimetinib with modified gemcitabine and nab-paclitaxel against the standard chemotherapy combination.

IMRX trades below its yearly high

Immuneering had a market capitalization of USD 148.5 million as of October 5, 2026, while its 52-week range stood at USD 3.86 to USD 8.48. The stock was last at USD 4.09 at 9:36 a.m. ET on Nasdaq, with a session change of 0.49 percent.